Life science investor Longitude Capital will use its $325M fund in later-stage deals
Longitude Capital will use its new $385 million fund to invest in later-stage life science companies. Longitude made the announcement Wednesday, but word had leaked out about the size of the fund (oversubscribed) in the past several weeks. In its release, Longitude co-founder Juliet Tammenoms Bakker reiterated the fund strategy of targeting “primarily mid-stage to […]